ABSTRACT
Introduction (3 rd paragraph)
METHODS

Protocol and registration 5
Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
Methods/Search strategy Eligibility criteria 6
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
Methods/Inclusion/exclusion criteria Information sources 7
Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Methods/Search strategy Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Methods/Search strategy Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Figure 1
Data collection process 10
Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Methods/Data extraction
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Methods/Data extraction and Methods/Quality assessment, Table 1, Table  2 and Supplementary Table  S1 Risk of bias in individual studies
12
Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Methods/Statistics
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2 ) for each meta-analysis.
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS
Study selection 17
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. Figure 1 and Results/Eligible articles Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Results/Study characteristics, Table 1 and  Table 2 Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). 
DISCUSSION
Summary of evidence 24
Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
Discussion (1 st paragraph)
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). Abbreviations: H-W P, P value for Hardy-Weinberg equilibrium test. For "Q1: Representativeness of cases", 2 denotes "Consecutive/randomly selected from case population with clearly defined random frame", 1 denotes "Consecutive/randomly selected from case population without clearly defined random frame or with extensive inclusion criteria" and 0 denotes "Method of selection not described". For "Q2: Representativeness of controls", 2 denotes "Controls were consecutive/randomly drawn from the same area (ward/community) as cases with the same criteria", 1 denotes "Controls were consecutive/randomly drawn from a different area than cases" and 0 denotes "Not described". For "Q3: Ascertainment of cancer cases", 1 denotes "Clearly described objective criteria for diagnosis of cancer" and 0 denotes "Not described". For "Q4: Ascertainment of controls", 2 denotes "Clinical examinations were performed on controls to prove that controls did not have cancer", 1 denotes "Article merely stated that controls were subjects who did not have cancer; no proof provided" and 0 denotes "Not described". For "Q5: Ascertainment of genotyping examination", 1 denotes "Genotyping done under ""blind"" conditions" and 0 denotes "Unblinded or not mentioned". For "Q6: Test for Hardy-Weinberg equilibrium", 2 denotes "Hardy-Weinberg equilibrium in control group", 1 denotes "Hardy-Weinberg disequilibrium in control group" and 0 denotes "Hardy-Weinberg equilibrium not checked". For "Q7: Association assessment", 2 denotes "Assessed association between genotypes and cancer with appropriate statistic and adjusting confounders", 1 denotes "Assessed association between genotypes and cancer with appropriate statistic without adjusting confounders" and 0 denotes "Inappropriate statistic used".
